Tostanoski Lisa H, Chandrashekar Abishek, Patel Shivani, Yu Jingyou, Jacob-Dolan Catherine, Chang Aiquan, Powers Olivia C, Sellers Daniel, Gardner Sarah, Barrett Julia, Sanborn Owen, Stephenson Kathryn E, Ansel Jessica L, Jaegle Kate, Seaman Michael S, Porto Maciel, Lok Megan, Spence Brittany, Cayer Kathleen, Nase Danielle, Holman Shaikim, Bradette Heath, Kar Swagata, Andersen Hanne, Lewis Mark G, Cox Freek, Tolboom Jeroen T B M, de Groot Anne Marit, Heerwegh Dirk, Le Gars Mathieu, Sadoff Jerald, Wegmann Frank, Zahn Roland C, Schuitemaker Hanneke, Barouch Dan H
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
NPJ Vaccines. 2022 Jan 10;7(1):2. doi: 10.1038/s41541-021-00427-z.
SARS-CoV-2 Spike-specific binding and neutralizing antibodies, elicited either by natural infection or vaccination, have emerged as potential correlates of protection. An important question, however, is whether vaccine-elicited antibodies in humans provide direct, functional protection from SARS-CoV-2 infection and disease. In this study, we explored directly the protective efficacy of human antibodies elicited by Ad26.COV2.S vaccination by adoptive transfer studies. IgG from plasma of Ad26.COV2.S vaccinated individuals was purified and transferred into naïve golden Syrian hamster recipients, followed by intra-nasal challenge of the hamsters with SARS-CoV-2. IgG purified from Ad26.COV2.S-vaccinated individuals provided dose-dependent protection in the recipient hamsters from weight loss following challenge. In contrast, IgG purified from placebo recipients provided no protection in this adoptive transfer model. Attenuation of weight loss correlated with binding and neutralizing antibody titers of the passively transferred IgG. This study suggests that Ad26.COV2.S-elicited antibodies in humans are mechanistically involved in protection against SARS-CoV-2.
由自然感染或疫苗接种引发的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白的结合抗体和中和抗体已成为潜在的保护相关因素。然而，一个重要的问题是，人类疫苗接种引发的抗体是否能直接提供针对SARS-CoV-2感染和疾病的功能性保护。在本研究中，我们通过过继转移研究直接探究了Ad26.COV2.S疫苗接种引发的人类抗体的保护效力。从接种Ad26.COV2.S的个体血浆中纯化出免疫球蛋白G（IgG），并将其转移至未接触过相关抗原的叙利亚金黄地鼠受体中，随后对这些地鼠进行SARS-CoV-2鼻内攻毒。从接种Ad26.COV2.S的个体中纯化出的IgG在受体地鼠攻毒后对体重减轻提供了剂量依赖性保护。相比之下，从接受安慰剂的个体中纯化出的IgG在这种过继转移模型中未提供保护。体重减轻的减轻与被动转移的IgG的结合抗体和中和抗体滴度相关。本研究表明，人类中Ad26.COV2.S引发的抗体在机制上参与了针对SARS-CoV-2的保护。
Zotero 插件
